EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Long-Term Safety and Effectiveness of Canakinumab in Patients with MKD/HIDS: Interim Analysis of the RELIANCE Registry

Prasad T Oommen, Tilmann Kallinich, Juergen Rech, Norbert Blank, Julia Weber-Arden, Jasmin B Kuemmerle-Deschner

Rheumatology and Therapy · 2025-02 · 12 (1) · 137-155

DOI: 10.1007/s40744-024-00733-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Rheumatology and Therapy, online erschienen am 26.12.2024. Verfasst von Prasad T Oommen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Paediatric Rheumatology, Department of Paediatric Oncology, Haematology and Clinical Immunology, Medical Faculty, Heinrich-Heine-Universi…. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Novartis Pharma AG.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

Autoinflammatory diseaseCanakinumabFever syndromesHyperimmunoglobulin-d syndromeMevalonate kinase deficiency

Autor:innen und Institutionen

  • Division of Paediatric Rheumatology, Department of Paediatric Oncology, Haematology and Clinical Immunology, Medical Faculty, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany. Prasad.Oommen@med.uni-duesseldor…
  • Department of Paediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité Universitätsmedizin, Berlin, Germany.
  • Deutsches Rheuma-Forschungszentrum (DRFZ), An Institute of the Leibniz Association, Berlin, Germany.
  • German Center for Child and Adolescent Health (DZKJ), Partner Site Berlin, Berlin, Germany.
  • Department of Internal Medicine 3, Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany.
  • DZI (Deutsches Zentrum Für Immuntherapie), Erlangen, Germany.

Förderung

  • Novartis Pharma AG

Zitieren

APA

Oommen, P. T., Kallinich, T., Rech, J., Blank, N., Weber-Arden, J., & Kuemmerle-Deschner, J. B. (2025). Long-Term Safety and Effectiveness of Canakinumab in Patients with MKD/HIDS: Interim Analysis of the RELIANCE Registry. Rheumatology and Therapy, 12(1), 137-155. https://doi.org/10.1007/s40744-024-00733-7

Vancouver

Oommen PT, Kallinich T, Rech J, Blank N, Weber-Arden J, Kuemmerle-Deschner JB. Long-Term Safety and Effectiveness of Canakinumab in Patients with MKD/HIDS: Interim Analysis of the RELIANCE Registry. Rheumatology and Therapy. 2025;12(1):137-155. doi:10.1007/s40744-024-00733-7

BibTeX
@article{Oommen2025,
  author = {Oommen, Prasad T and Kallinich, Tilmann and Rech, Juergen and Blank, Norbert and Weber-Arden, Julia and Kuemmerle-Deschner, Jasmin B},
  title = {Long-Term Safety and Effectiveness of Canakinumab in Patients with MKD/HIDS: Interim Analysis of the RELIANCE Registry},
  journal = {Rheumatology and Therapy},
  year = {2025},
  volume = {12},
  number = {1},
  pages = {137--155},
  doi = {10.1007/s40744-024-00733-7}
}
Kostenlos starten →